Short-term effect of miglustat in every day clinical use in treatment-naive or previously treated patients with type 1 Gaucher's disease

Haematology Department, Miguel Servet University Hospital, Zaragoza, Spain. pgiraldo@salud.aragon.es

In a prospective, open-label study, 25 patients with mild-to-moderate type 1 Gaucher's disease (GD1) were treated with miglustat (Zavesca), an oral glucosylceramide synthase inhibitor, over 12 months. Of the 25 patients, 10 were therapy-naive and 15 had previously received enzyme replacement therapy (ERT). Clinical status, blood parameters, biomarkers, and organomegaly were assessed at baseline at 6 months and at 12 months. At 6 months the previously untreated patients showed a mean increase in hemoglobin of 0.77 g/dL, platelet counts improved or remaining stable, chitotriosidase and CCL18 decreased. These results were similar to those observed in 40 Spanish GD1 patients on ERT. Bone marrow infiltration cleared at 12 months. In the previously treated group, clinical and hematologic parameters and biomarkers were maintained/ improved at 12 months. Miglustat was well tolerated. The efficacy of miglustat treatment after 6 months was comparable to that of ERT.

This article has been cited by other articles:

				M. Di Rocco, F. Giona, F. Carubbi, S. Linari, F. Minichilli, R. O. Brady, G. Mariani, and M. D. Cappellini A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease Haematologica, August 1, 2008; 93(8): 1211 - 1218. [Abstract] [Full Text] [PDF]

				J. Schmitz, L. W. Poll, and S. v. Dahl Therapy of adult Gaucher disease Haematologica, February 1, 2007; 92(2): 148 - 152. [Full Text] [PDF]